ZA200504594B - Composition for osteoporosis - Google Patents
Composition for osteoporosis Download PDFInfo
- Publication number
- ZA200504594B ZA200504594B ZA200504594A ZA200504594A ZA200504594B ZA 200504594 B ZA200504594 B ZA 200504594B ZA 200504594 A ZA200504594 A ZA 200504594A ZA 200504594 A ZA200504594 A ZA 200504594A ZA 200504594 B ZA200504594 B ZA 200504594B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- vitamin
- calcium
- source
- magnesium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 71
- 208000001132 Osteoporosis Diseases 0.000 title claims description 13
- 239000011575 calcium Substances 0.000 claims description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 23
- 229910052791 calcium Inorganic materials 0.000 claims description 23
- 108010011619 6-Phytase Proteins 0.000 claims description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 15
- 229940085127 phytase Drugs 0.000 claims description 15
- 229930003316 Vitamin D Natural products 0.000 claims description 14
- 235000019166 vitamin D Nutrition 0.000 claims description 14
- 239000011710 vitamin D Substances 0.000 claims description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 14
- 229940046008 vitamin d Drugs 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 229930003448 Vitamin K Natural products 0.000 claims description 11
- 229910052749 magnesium Inorganic materials 0.000 claims description 11
- 235000001055 magnesium Nutrition 0.000 claims description 11
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 11
- 235000019168 vitamin K Nutrition 0.000 claims description 11
- 239000011712 vitamin K Substances 0.000 claims description 11
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- 229940046010 vitamin k Drugs 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 229940091250 magnesium supplement Drugs 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 229910052796 boron Inorganic materials 0.000 claims description 5
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 5
- 239000001354 calcium citrate Substances 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 241000228245 Aspergillus niger Species 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940085493 magnesium amino acid chelate Drugs 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 229960000869 magnesium oxide Drugs 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- 239000013522 chelant Substances 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- -1 selenium amino acid Chemical class 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 2
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229940083982 sodium phytate Drugs 0.000 description 2
- 239000011576 zinc lactate Substances 0.000 description 2
- 235000000193 zinc lactate Nutrition 0.000 description 2
- 229940050168 zinc lactate Drugs 0.000 description 2
- PNNHLULHRSZWPG-UHFFFAOYSA-J 1,5-dihydroxypentan-3-yl phosphate;2,3-dihydroxypropyl phosphate;manganese(2+) Chemical compound [Mn+2].[Mn+2].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O PNNHLULHRSZWPG-UHFFFAOYSA-J 0.000 description 1
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011564 manganese citrate Substances 0.000 description 1
- 235000014872 manganese citrate Nutrition 0.000 description 1
- 229940097206 manganese citrate Drugs 0.000 description 1
- 150000002697 manganese compounds Chemical class 0.000 description 1
- 239000011584 manganese glycerophosphate Substances 0.000 description 1
- 235000018348 manganese glycerophosphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
- Ao QUEST
COMPOSITION FOR OSTEOPOROSIS
This invention relates to a composition and to the preparation of a composition, for use in the prophylaxis or treatment of osteoporosis in mammals, including humans.
Osteoporosis is a metabolic borye disease characterised by a micro- architectural deterioration of bone tissue and a loss of bone mass/density that results in increased bone fragility. The lifetime risk of osteoporotic bone fractures is approximately 40% in women and approximately 15% in men.
The risk of bone fractures due to an increased bone fragility increases with age, if the underlying osteoporosis is not treated. Prevention of osteoporosis is therefore the most preferred strate gy in overcoming the disease.
It is known that calcium is the single most important component in bone tissue. A calcium deficiency in the blood plasma or insufficient uptake of calcium from the blood plasma into bone could therefore lead to osteoporosis.
Accordimg to the present invention, there is provided the wise of a source of calcium, a source of magnesium, vitamin K, vitamin D a.nd phytase in the preparation of a composition for use in the treatment or prophylaxis of osteoporosis of a mammal.
In this specification a mammal includes a human.
Preferably, at least 300 mg of calcium is administered to the mammal on a day dosage basis.
Accordirag to a further aspect of the invention there is provi ded a day dosage composition in the form of one or more dosage units, the composition comprising a source of calcium; a source of magnesium, vitamin K; vitamin D; and phytase, and wherein the composition contains at least 300 mg. of calcium on a day dosage basis.
Preferably the composition is for use in the prophylaxis and/or treatment of osteoporosis.
The one or more dosage units may be in the form of one or more capsules or tablets.
The composition preferably includes at least 11,25 FTU, more preferably at least to 22.5 FTU, and in some cases even 45FTU (or even more) on a day dosage basis, of phytase.
The phytase may comprise a Aspergillus niger derived phytase.
In a preferred embodiment of the invention, the vitamin K is vitamiin K;. The composition may include at least 15 pug of vitamin K, on a day dosage basis, preferably at least 30 pug and even 60 ug (or even more) on a day dosage basis
Preferably the vitamin D is vitamin D3. The composition may includ e at least 120 Interreational Units (1U) of vitamin D, on a day dosage basis, pre=ferably at least 240 BU and even 480 IU (or even more) on a day dosage basis.
The source of calcium in the composition may be a calcium salt such as calcium citrate and/or calcium carbonate. Preferably, the source of calcium comprises calcium citrate and calcium carbonate. The composition preferably includes at least 300 mg of calcium, on a day dosage basis, preferably at least 600 mg arad even 1200 mg (or even more) on a day dosage basis.
The source of magnesium in the composition may be magnesium «citrate or magnesiurm oxide or magnesium amino acid chelate, preferably magnesium oxide. The: composition may include at least 40 mg of magnesium, on a day dosage basis, preferably at least 80 mg and even 160 mg (or even more) on a day dosage basis.
The composition preferably includes at least one or more additional vitamins, preferably at least one vitamin selected from the group consisting of vitamin
C, vitamin Bg vitamin B,, and folic acid. Preferably the composition includes all four of these vitamins.
The composition may include at least 30 mg of vitamin C on a day dosage basis, preferably at least 60 mg and even 120 mg (or even more) on a day dosage basis.
The composition may include at least 0,9 mg of vitamin Bs on a day dosage basis, preferably at least 1,8 mg and even 3.6 mg (or even more) on a day dosage basis.
The composition may include at least 1,125 pg of vitamin By; on a day dosage basis, preferably at least 2,25 ug and even 4.5 ug (or even more) on a day dosage basis.
The composition may include at least 100 pg of folic acid on a day dosage basis, preferably at least 200 pg and even 4 00 pg (or even more) on a day dosage basis.
The composition preferably also includes one or more elements, preferably an element selected from the group consisting of copper, manganese, zinc,
selenium, silicon and boron. Preferably the composition includes a combimation of all of the above elements.
The copper may be provided as a copper compound, such as copper sulphate anhydrous. The composition may include at least 187,5 ug of copper, on a day dosage basis, preferably at least 375 pg and even 750 pg (or even more) on a day dosage basis.
The manganese may be provided as a manganese compound, such as manganese citrate or manganese glycerophosphate or mangamese sulphate.
The composition may include at least 0,75 mg of manganese or a day dosage basis, preferably at least 1,5 mg and even 3 mg (or even m ore) on a day dosage basis.
The zinc maybe provided as a zinc compound, such as zinc gluconate and/or zinc lactate. The composition may include at least 3,75 mg of zinc on a day dosage basis, preferably at least 7,5 mg and even 15 mg (or ev en more) on a day dosage basis.
The serlenium may be provided as a selenium compound, such as selenium amino acid chelate. The composition may include at least, 10 Lag of selenium on a day dosage basis, preferably at least 20 ug and even 40 pg (or even more) on a day dosage basis.
The silicon may be provided as a silicon compound, such as silicon dioxide or preferably, magnesium silicate. The composition may include at least 0,375 mg of silicon on a day dosage basis, preferably at least 0,75 mg and even 1,5 mg (or even more) on a day dosage basis.
The boron may be provided as a boron compound, such as boric acid or boron amino acid chelate. The composition may include at least 0,125 mg of boron on a day dosage basis, preferably at least 0,25 mg and even 0,5 mg (or even more) on a day dosage basis.
The composition may also include conventional formulating agents, carriers and the like.
According to a preferred embodiment of the invention, the mammal is a human.
According to a further aspect of the invention, there is provided a composition comprising a source of calcium, a so urce of magnesium; vitamin K; vitamin D; and phytase, and wherein the ratio of vitamin D to calcium in the composition is 1 IU vitamin D to at least 2,5 nng calcium, for use in the treatment or prophylaxis of osteoporosis of a mammal.
The invention will now be further described by means of the following non- limiting example.
ECA UE IE LI
: To 2 = 3 EAE RE
The following ingredients in the amounts indicated were used to prepare a composition according to the present invention in tablet form:
INGREDIENTS CONTENT PER TABLET
1. Calcium carbonate and calcium | 600 mg Ca citrate * 2. Vitamin K, 30 ug 4. Phytase 22,5 FTU=15mg 5. Magnesium oxide 80 mg Mg a LL. I 8. Folic acid 200 pug 9. Vitamin Biz 2,25 ug 10. Copper sulphate anhydrous 375 ug Cu 11. Manganese sulphate 1500 pg Mn 12. Zinc lactate 7,5 mg Zn 13. Selenium amino acid chelate 20 ug Se 14. Magnesium silicate 0,75 mg Si 15. Boric acid 250 ug B * Calcium citrate provides 20% of the calcium and calcium carbonate the rest. 18) = International Unit 1 FTU = that quantity of phytase that will liberate inorganic phosphate from sodium phytate at one micromole per minute, based on a 30 minute hydrolysis of sodium phytate at 37°C and pH 5,5.
Compounds 2, 3, 7, 8 and 9 were blended and then blended with compound 6 to form a sub-blend A. Compounds 10, 11, 12, 13, 14 and 15 were blended and then blended with calcium citrate to form a sub-blend B. Compound <4 supplied as Phytase by National Enzyme Company, US and magnesium stearate (24 mg) were then blended with sub-blend B to form sub-blend C.
Calcium carbonate and compound 5 were then blended with sub-blend A and
Cto produce the final blend from which tablets were pressed.
According to this example, the composition is for administration of the composition in a dosage of: se omwoos 51 years —- 64 years 1-2 tablets daily (women on Estrogen therapy and te 51 years + (women not on Estrogen 2 tablets daily =
The dosages of the ingredients indicated above may be varied in other embodiments of the invention.
It will be appreciated that many variations in detail are possible without thereby departing from the scope and sp irit of the invention.
Claims (22)
1. The use of a source of calcium, a source of magnesium, vitamin K, vitamin D and phytase in the preparation of a composition for use in the treatment or prophylaxis of osteoporosis of a mammal.
2. The use of claim 1 wherein at least 300 mg of calcium is administered to the mammal on a day dosage basis.
3. The use of either one of claims 1 or 2 wherein the composition is in the form of one or more dosage units.
4. The use of claim 3 wherein the one or more dosage units is in the form of one or more capsules or tablets.
5. A day dosage composition in the form of one or more dosage units, the composition comprising a source of calcium; a source of magnesium: vitamin K; vitamin D; and phytase, and wherein the composition contains at least 300 mg of calcium on a day dosage basis.
6. The composition of claim 5 which is for use in the prophylaxis and/or treatment of osteoporosis.
7. The composition of either one of claims 5 or 6 wherein the one or more dosage units is in the form of one or more capsules or tablets.
8. The composition of any one of claims 5 to 7 which includes at least 11,25 FTU, on a day dosage basis, of phytase.
9. The composition of any one of claims 5 to 8 wherein the phytase is a Aspergillus niger derived phytase.
10. The composition of any one of claims 5 to 9 wherein the vitamin K is vitamin Kj.
11. The composition of any one of claims 5 to 10 wherein the composition includes at least 15 pug of vitamin K, on a day dosage basis.
12. The composition of any one of claims 5 to 11 whe rein the vitamin D is LS vitamin Dj,
13. The composition of any one of claims 5 to 12 wherein the composition includes at least 120 Intemational Units (IU) of vitamin D, on a day dosage basis.
14. The composition of any one of claims 5 to 13 wh erein the source of calcium in the composition is a calcium salt.
15. The composition of claim 14 wherein the source of calcium comprises calcium citrate and calcium carbonate.
- SUE I BEES ARS A 9h
16. The composition of any one of claims 5 to 15 wherein the source of magnesium in the composition is magnesium citrate or magnesium oxide or magnesium amino acid chelate.
17. The composition of any one of claims 5 to 16 wherein the composition includes at least 40 rg of magnesium, on a day dosage basis.
18. The composition of any one of claims 5 to 17 wherein the composition includes at least one vitamin selected from the group consisting of vitamin C, vitamin Bg, vitamin By» and folic acid.
19. The composition of any one of claims 5 to 18 wherein the composition includes at least one element selected from the group consisting of copper, manganese, zinc, selenium, silicon and boron.
20. The use of any one of claims 1 to 4 wherein the mammal is a human.
21. A composition comprising a source of calcium, a source of magnesium; vitamin K; vitamin D; and phytase, and wherein the ratio of vitamin D to calcium in the composition is 1 IU vitamin D to at least 2,5 mg calcium, for use in the treatment or prophylaxis of osteoporosis of a mammal.
22. A composition including the ingredients as set out in the table of the example. ’s Dated this 6™ day of JE X05 13 Patent ll Agent for the Applicant
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200504594A ZA200504594B (en) | 2004-08-03 | 2005-06-06 | Composition for osteoporosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200406189 | 2004-08-03 | ||
| ZA200504594A ZA200504594B (en) | 2004-08-03 | 2005-06-06 | Composition for osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504594B true ZA200504594B (en) | 2006-07-26 |
Family
ID=38181283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504594A ZA200504594B (en) | 2004-08-03 | 2005-06-06 | Composition for osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| ZA (1) | ZA200504594B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2028362B1 (en) * | 2021-06-01 | 2022-12-14 | Intracare Bv | Composition for improving calcium and phosphorus regulation in poultry and uses thereof |
-
2005
- 2005-06-06 ZA ZA200504594A patent/ZA200504594B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2028362B1 (en) * | 2021-06-01 | 2022-12-14 | Intracare Bv | Composition for improving calcium and phosphorus regulation in poultry and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sampaio et al. | Systemic fluoride | |
| Prystupa | Fluorine—a current literature review. An NRC and ATSDR based review of safety standards for exposure to fluorine and fluorides | |
| Rondanelli et al. | Pivotal role of boron supplementation on bone health: A narrative review | |
| Lambrinoudaki et al. | Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women | |
| RU2008118101A (en) | MIXTURE OF IRON AND COPPER SALTS, MASKING METAL TASTE | |
| RU2352139C2 (en) | Method of increasing bone strength of pigs, respective composition, its use, feed stuff and premix for pigs | |
| US20150209249A1 (en) | Enhanced Anti-Carious Dentifrices, Rinses, Lozenges, Candies and Chewing Gums and Methods of Using Same | |
| Fernando et al. | The prebiotic effect of CPP-ACP sugar-free chewing gum | |
| Lynch et al. | Microelements: Part I: Zn, Sn, Cu, Fe and I | |
| US9308222B2 (en) | Formulas comprising highly soluble elements and vitamins for the prevention and amelioration of osteoporosis | |
| Shen et al. | Effects of soy and bovine milk beverages on enamel mineral content in a randomized, double-blind in situ clinical study | |
| US6316008B1 (en) | Combination of zinc ions and vitamin C and method of making | |
| WO2008031602A1 (en) | Food supplementation composition containing one or more vitamin d3 compounds and one or more magnesium salts | |
| Lippert | Macroelements: Ca, Na, K, P, Cl | |
| Doğan | Relation of trace elements on dental health | |
| ZA200504594B (en) | Composition for osteoporosis | |
| CN108652996A (en) | A kind of oral care health promoting liquid containing lysozyme | |
| CA2979305C (en) | Use of zinc and copper gluconate in the treatment of methicillin-resistant staphylococcus aureus | |
| Kinoshita et al. | Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy | |
| Gerber | A review of mineral absorption with special consideration of chelation as a method to improve bioavailability of mineral supplements | |
| US6936286B2 (en) | Healthy bone formulation | |
| Cho et al. | Efficacy of a once-monthly pill containing ibandronate and cholecalciferol on the levels of 25-hydroxyvitamin D and bone markers in postmenopausal women with osteoporosis | |
| US9974717B2 (en) | Phosphate composition for dental strengthening | |
| JP6479547B2 (en) | Veterinary dental care composition | |
| US20200254009A1 (en) | Potassium enriched topical formulations for pain relief and sleep aid |